Hologic, Inc. (HOLX)
| Market Cap | 17.40B |
| Revenue (ttm) | 5.39B |
| Net Income (ttm) | 1.55B |
| Shares Out | 249.38M |
| EPS (ttm) | 6.06 |
| PE Ratio | 11.52 |
| Forward PE | 16.81 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,279,777 |
| Open | 71.99 |
| Previous Close | 71.46 |
| Day's Range | 69.70 - 72.27 |
| 52-Week Range | 66.26 - 81.04 |
| Beta | 1.09 |
| Analysts | Buy |
| Price Target | 81.09 (+16.2%) |
| Earnings Date | Jul 27, 2022 |
About HOLX
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-... [Read more...]
Financial Performance
In 2021, Hologic's revenue was $5.63 billion, an increase of 49.14% compared to the previous year's $3.78 billion. Earnings were $1.87 billion, an increase of 67.82%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for HOLX stock is "Buy." The 12-month stock price forecast is 81.09, which is an increase of 16.21% from the latest price.
News
Is Most-Watched Stock Hologic, Inc. (HOLX) Worth Betting on Now?
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hologic (HOLX) New Products Aid Growth, Margin Pressure Stays
Hologic's (HOLX) core molecular diagnostics franchise is growing driven by strong uptake in newer assays such as vaginitis panel and menu within the virology product line.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Why Is Hologic (HOLX) Up 6.7% Since Last Earnings Report?
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?
Hologic (HOLX) Gets CE Mark for Fusion Molecular Assays
Hologic's (HOLX) two new molecular assays monitor transplant patients for EBV and BKV.
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hologic Announces European CE Mark for Molecular Assays for Use with Transplant Patients
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #EpsteinBarr--Hologic Announces European CE Mark for Molecular Assays for Use with Transplant Patients
Stocks This Week: Buy Hologic And Paychex
Stocks are likely to rally, and this pair of equities are likely to lead.
Here's Why Investors Should Retain Hologic (HOLX) Stock for Now
Investors are optimistic about Hologic's (HOLX) better-than-expected results and robust segmental growth.
Hologic Board Member, Sally W. Crawford, Recognized As NACD Directorship 100™ Honoree
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #NACD--Hologic Board Member, Sally W. Crawford, Recognized As NACD Directorship 100™ Honoree
Final Trades: Charles Schwab, Merck, Hologic & more
The "Halftime Report" traders give their top picks to watch for the second half.
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic Announces FDA Approval of Aptima® CMV Quant Assay for Human Cytomegalovirus
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #Aptima--Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) approved its Aptima CMV Quant assay to quantify the viral loa...
Hologic to Webcast Presentation at Upcoming Investor Conference
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #bofaconference--Hologic to Webcast Presentation at Upcoming Investor Conference
Lower COVID-19 Assay Sales Weighs On Hologic's Q2 Revenue
Hologic Inc (NASDAQ: HOLX) reported Q2 FY22 sales of $1.44 billion, down 7% Y/Y, and beating the consensus Wall Street estimate for revenues of $1.29 billion. Lower sales of COVID-19 assays primarily dr...
Hologic (HOLX) Q2 Earnings Surpass Estimates, 2022 View Up
Hologic's (HOLX) second-quarter 2022 revenues decline year over year primarily due to lower COVID-19 assay sales compared to the prior year.
Chip shortage ‘impacts women's health': Hologic CEO
Steve MacMillan, the CEO of medical technology company Hologic, warned that the global semiconductor chip shortage “impacts women's health.”
Hologic (HOLX) Q2 Earnings and Revenues Surpass Estimates
Hologic (HOLX) delivered earnings and revenue surprises of 33.55% and 12.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Hologic Announces Financial Results for Second Quarter of Fiscal 2022
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #HOLX--Hologic, Inc. (Nasdaq: HOLX) announced today the Company's financial results for the fiscal second quarter ended March 26, 2022. “In our second quart...
Is a Surprise Coming for Hologic (HOLX) This Earnings Season?
Hologic (HOLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Now Includes Breast Cancer Index™ to Guide D...
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #ASCO--ASCO Clinical Practice Guideline Now Includes Breast Cancer Index™ to Guide Decisions about Extended Endocrine Therapy
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic (HOLX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic (HOLX) Crossed Above the 20-Day Moving Average: What That Means for Investors
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Why Hologic (HOLX) is Poised to Beat Earnings Estimates Again
Hologic (HOLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.